Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interleukin-3 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Interleukin-3 | DRUG | - |
Inclusion Criteria Patients must have: * HIV seropositivity by Western blot. * Advanced ARC or AIDS as defined by CDC. * Cytopenia defined as total peripheral leukocyte count of \< 3,000 cells/mm3 or platelet count of \< 100,000 cells/mm3 or serum hemoglobin \< 10 g/dl. * Anticipated life expectan...
Top 20 of 28 competitors
Interleukin-3 is an investigational small molecule being studied for the treatment of HIV infections, specifically in patients with cytopenia. It was evaluated in a Phase 1 clinical trial to assess its safety, tolerance, and biological effects in HIV-infected patients with cytopenia. The drug is still in clinical development and is not approved.
Interleukin-3 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company conducted a Phase 1 clinical trial of the drug in the United States for HIV infections with cytopenia.
Interleukin-3 is in Phase 1 clinical development. A single Phase 1, open-label trial has been completed to evaluate the safety, tolerance, and biological effects of the drug in HIV-infected patients with cytopenia. The drug remains investigational and has not received FDA approval.
Interleukin-3 has one completed clinical trial, identified as NCT00002258. This Phase 1, open-label trial evaluated the safety, tolerance, and biological effects of SDZ ILE-964 (recombinant human interleukin-3) in HIV-infected patients with cytopenia. The trial was conducted in the United States and enrolled adults aged 18 years and older.
Interleukin-3 is a recombinant human interleukin-3, which is a cytokine that stimulates the production and differentiation of blood cells. In the context of HIV infections, it is being studied for its potential to address cytopenia, a condition characterized by low blood cell counts.